We need to bring R0 Devabhaktuni Srikrishna  1 , Kris Sachsenmeier  2 Affiliations Expand Affiliations 1 Breakbio Corp., 63 Bovet Road, #418, San Mateo, CA, 94402, USA. sri.devabhaktuni@gmail.com. 2 Translational Medicine-Oncology, AstraZeneca, 35 Gatehouse Drive, Waltham, MA, USA. PMID: 34311780 PMCID: PMC8312206 DOI: 10.1186/s13073-021-00940-9 Free PMC article Item in Clipboard

Devabhaktuni Srikrishna, Kris Sachsenmeier, Devabhaktuni Srikrishna, Kris Sachsenmeier

Abstract

If each cancer cell produces on average more than one cancer cell, we see a net growth of the tumors and metastases and vice versa. We review recent clinical results for microsatellite stable metastatic colorectal cancer (MSS-mCRC) suggesting immunotherapy combinations with personalized vaccines, checkpoint inhibitors, targeted therapies, multikinase inhibitors, chemotherapies, and radiation that simultaneously slow cancer cell growth rate and enhance T cell killing rate of cancer cells may in future synergize to control the disease.

Trial registration: ClinicalTrials.gov NCT01970358 NCT03548467 NCT03739931.

Conflict of interest statement

Devabhaktuni Srikrishna is a co-founder of Breakbio Corp. which is researching novel immunotherapy combinations for Microsatellite Stable Metastatic Colorectal Cancer (MSS-mCRC). Kris Sachsenmeier has held and holds positions in translational research at AstraZeneca and Takeda Oncology, respectively, and is an unpaid advisor to Breakbio Corp.

© 2021. The Author(s).

References

    1. Havel JJ, Chowell D, Chan TA. The evolving landscape of biomarkers for checkpoint inhibitor immunotherapy. Nat Rev Cancer. 2019;19(3):133–150. doi: 10.1038/s41568-019-0116-x.
    1. Shemesh CS, Hsu JC, Hosseini I, Shen BQ, Rotte A, Twomey P, Girish S, Wu B. Personalized cancer vaccines: clinical landscape, challenges, and opportunities. Mol Ther. 2021;29(2):555–570. doi: 10.1016/j.ymthe.2020.09.038.
    1. Meric-Bernstam F, Larkin J, Tabernero J, Bonini C. Enhancing anti-tumour efficacy with immunotherapy combinations. Lancet. 2021;397(10278):1010–1022. doi: 10.1016/S0140-6736(20)32598-8.
    1. Pagès F, Mlecnik B, Marliot F, Bindea G, Ou FS, Bifulco C, Lugli A, Zlobec I, Rau TT, Berger MD, et al. International validation of the consensus Immunoscore for the classification of colon cancer: a prognostic and accuracy study. Lancet. 2018;391(10135):2128–2139. doi: 10.1016/S0140-6736(18)30789-X.
    1. Sennino B, Litterman A, Gagnon J, Conroy A, Purandare B, Pan Z, Olivier D, Jacoby K, Peng S, Franzusoff A, Mandl SJ. P214 T cells precision engineered to express neoepitope-specific TCRs cloned from a patient with colorectal cancer, specifically target and kill relevant neoantigen-expressing tumor cells. 34th Annual Meeting & Pre-Conference Programs of the Society for Immunotherapy of Cancer (SITC 2019): part 1. J Iimmunother Cancer. 2019;7:282. doi: 10.1186/s40425-019-0763-1.
    1. Roberto M, Falcone R, Mazzuca F, Archibugi L, Castaldi N, Botticelli A, Osti MF, Marchetti P. The role of stereotactic body radiation therapy in oligometastatic colorectal cancer: Clinical case report of a long-responder patient treated with regorafenib beyond progression. Medicine. 2017;96(48):e9023. doi: 10.1097/MD.0000000000009023.
    1. Hiraki M, Nishimura J, Ohtsuka M, Shiomi H, Uemura M, Haraguchi N, Hata T, Hayashi T, Takemasa I, Mizushima T, Isohashi F, Yoshioka Y, Ogawa K, Doki Y, Mori M, Yamamoto H. Impact of stereotactic body radiotherapy on colorectal cancer with distant metastases. Oncol Rep. 2014;31(2):795–799. doi: 10.3892/or.2013.2871.
    1. Guinney J, Dienstmann R, Wang X, de Reyniès A, Schlicker A, Soneson C, Marisa L, Roepman P, Nyamundanda G, Angelino P, Bot BM, Morris JS, Simon IM, Gerster S, Fessler E, De Sousa E, Melo F, Missiaglia E, Ramay H, Barras D, Homicsko K, Maru D, Manyam GC, Broom B, Boige V, Perez-Villamil B, Laderas T, Salazar R, Gray JW, Hanahan D, Tabernero J, Bernards R, Friend SH, Laurent-Puig P, Medema JP, Sadanandam A, Wessels L, Delorenzi M, Kopetz S, Vermeulen L, Tejpar S. The consensus molecular subtypes of colorectal cancer. Nat Med. 2015;21(11):1350–1356. doi: 10.1038/nm.3967.
    1. Schmieder R, Hoffmann J, Becker M, Bhargava A, Müller T, Kahmann N, Ellinghaus P, Adams R, Rosenthal A, Thierauch KH, Scholz A, Wilhelm SM, Zopf D. Regorafenib (BAY 73-4506): antitumor and antimetastatic activities in preclinical models of colorectal cancer. Int J Cancer. 2014;135(6):1487–1496. doi: 10.1002/ijc.28669.
    1. Yu J, Green MD, Li S, Sun Y, Journey SN, Choi JE, Rizvi SM, Qin A, Waninger JJ, Lang X, Chopra Z, el Naqa I, Zhou J, Bian Y, Jiang L, Tezel A, Skvarce J, Achar RK, Sitto M, Rosen BS, Su F, Narayanan SP, Cao X, Wei S, Szeliga W, Vatan L, Mayo C, Morgan MA, Schonewolf CA, Cuneo K, Kryczek I, Ma VT, Lao CD, Lawrence TS, Ramnath N, Wen F, Chinnaiyan AM, Cieslik M, Alva A, Zou W. Liver metastasis restrains immunotherapy efficacy via macrophage-mediated T cell elimination. Nat Med. 2020;27(1):152–164. doi: 10.1038/s41591-020-1131-x.

Source: PubMed

Sponsorit ja yhteistyökumppanit

Sairaudet

Huumeiden interventiot

3
Tilaa